Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax combinations in R/R AML
NCT02670044Phase 1Completed
- Sponsor
- Roche
- Start
- Mar 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of venetoclax, cobimetinib and idasanutlin in acute myeloid leukemia (AML) (2 arms), sponsored by Roche. Primary endpoints: Dose Limiting Toxicities and Adverse Events. Started Mar 2016; status: completed.
02
Drugs
venetoclaxcobimetinibidasanutlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02670044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02670044.